GU Cancers 2021 | FGFRi treatment-emergent AEs in urothelial cancer

Arlene Siefker-Radtke, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the management of treatment-emergent adverse events (AEs) in patients with locally advanced or metastatic urothelial cancer treated in the second-line with the fibroblast growth factor receptor inhibitor (FGFRi), erdafitinib. Recommended management is to hold erdafitinib at grade 2 toxicities before reaching higher grades to avoid a longer duration of paused treatment. This interview took place during the 2021 Genitourinary Cancers Symposium.